 Apotex responded by noting that Olivieri had signed a confidentiality agreement as part of the drug trial and that informing participants about her concerns, the validity of which Apotex disputed, would violate that confidentiality agreement.In 1996, Apotex threatened to vigorously pursue legal remedies against her if she disclosed her conclusions to patients.Olivieri disclosed her concerns to her patients and Apotex ended the portion of the study in which she was participating.